Janssen shared Phase 2a data of our Dengue antiviral. Good news: JNJ-1802 induced antiviral activity against dengue virus in humans!
More information can be found in the J&J Press Release.
Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model
Related Posts
CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers
CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers
Sven_CD3May 6, 2025
KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease
KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease
Sven_CD3April 10, 2025
CD3 and the KULeuven Lab of Cellular Transport Systems Join Forces with SandboxAQ to Speed Identification of New Therapies for the treatment of Parkinson’s Disease
CD3 and the KULeuven Lab of Cellular Transport Systems Join Forces with SandboxAQ to Speed Identification of New Therapies for the treatment of Parkinson’s Disease
Sven_CD3November 29, 2024